The low cost of zinc sulfate ($0.05 /dose(21)) makes it an attractive therapeutic candidate compared to other drugs being evaluated for COVID-19 management such as remdesivir ($520.00 /dose(22)) or IL-6 blockers ($277.00 /600 mg dose of tocilizumab(23)). The gene discussed is IL6; the disease is COVID-19.